Dr. Khurram Jamil, M.D.
Chief Medical Officer, Galectin Therapeutics. Episode 1.
More than twenty years in hepatology and drug development at Organon, Ikaria, and Mallinckrodt, with a focus on MASH cirrhosis.
The conversation covers what drug development actually looks like from the inside: how a compound moves from a hypothesis to a trial, and why so much of the work is deciding what not to pursue.